SLBT (SL Science Holding) Total Debt per Share: $0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLBT SL Science Holding Ltd SLBT
12 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is SL Science Holding Total Debt per Share?

SL Science Holding SLBT +24.39% 12 Total Debt per Share is $0.00 as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

$0.00 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. SL Science Holding's Total Debt Per Share for the quarter that ended in Dec. 2025 was $0.00.

SL Science Holding Total Debt per Share Historical Data

* Premium members only.

The historical data trend for SL Science Holding's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding Total Debt per Share Chart

SL Science Holding Annual Data
Trend Dec23 Dec24 Dec25
Total Debt per Share
0.00 0.00 0.00

SL Science Holding Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Debt per Share 0.00 0.00 0.00 0.00 0.00
SLBT
12GF Score
SL Science Holding Ltd SLBT
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SL Science Holding Total Debt per Share Calculation

SL Science Holding's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.07+0.15)/560.76
=0.00

SL Science Holding's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.07+0.15)/560.76
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
SL Science Holding (SLBT) has a Total Debt per Share of $0.00 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on SL Science Holding and its competitors.
Is SL Science Holding's Total Debt per Share too high?
SL Science Holding's current Total Debt per Share is $0.00. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Total Debt per Share compare to DMRA and BCAX?
SL Science Holding's Total Debt per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on SL Science Holding and its competitors. SL Science Holding's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Total Debt per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SL Science Holding Business Description

Address No. 479 Chongyang Road, 11th Floor, Nangang District, Taipei, TWN, 115010
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score

Get the complete analysis for SLBT

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price